Forum Archive Index - October 2001

["Jeremy Ardley" <jeremy@ardley.org>]

Gerry,

 

The lack of product differentiation I refered to was in the monitoring and telemetry sides of their business.  I stated that the pump product you referrred to *may* be superior.

 

What I doubt is that the pump will translate into any form of mass market, or provide significant ROI.  It is a speculative stock at the wild end of the market.  It may well produce a short term return if enough people get a rush of blood to the head about it (joke intended :-) .  It will never produce a good return for a long term investor.

 

I ask a secondary question.  How did the topic of platelet destruction arise?  The answer is because of the work done with mechanical heart valves that have been in use for many years.  Platelet destuction and clot formation have been a constant plague.  If the technology is so good, why not produce a non-clotting valve?  Why go the full monty for a pump without the preliminary steps of less invasive devices?

 

Jeremy

There is a significant product differentiaton. You listed them in your previous post! And it is blatantly stated in the literature. Destruction of blood platelets is the greatest fear of surgeons who implant today's devices.

 

Anyway, the purpose of my post was to inform the Holders of MMD shares. They asked me to do so. 

 

And yes, when there is more news, I shall inform them again in a post.